



uniQure to Participate in Multiple Upcoming Industry Conferences

October 31, 2018

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Oct. 31, 2018 (GLOBE NEWSWIRE) -- [uniQure N.V.](#) (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in the following upcoming conferences in November:

- **World Orphan Drug Congress in Barcelona, Spain**

- [Sander van Deventer](#), M.D., Ph.D., chief scientific officer at uniQure, will participate in a panel called "Executive industry insights - Why are we pursuing the same diseases?" on Wednesday, November 7 at 9:30 a.m. CET.

- **uniQure Research & Development Day in New York City**

- uniQure will host a Research and Development Day in New York for its research analysts and institutional investors on Monday, November 19 from 8:30 a.m. to 12:00 p.m. ET. The event will feature presentations from senior management, company scientists and medical experts on the expansion of our research pipeline and enhancements in technology. The live webcast can be accessed through the link displayed in the [Investor section of the uniQure website](#).

- **Evercore ISI Conference at the Boston Harbor Hotel in Boston, MA**

- [Matt Kapusta](#), chief executive officer at uniQure, will present a corporate update on Tuesday, November 27 at 3:50 p.m. ET. The live webcast can be accessed through the link displayed in the [Investor section of the uniQure website](#). The webcast replay will be available for at least 72 hours following the live event.

- **Dutch Life Sciences Conference at Leiden Bio Science Park in the Netherlands**

- [Sander van Deventer](#), M.D., Ph.D., chief scientific officer at uniQure, will present as part of the afternoon session "Regenerative medicines: taking science to the patients" on Thursday, November 29 at 1:30 p.m. CET.

- **Barclays Gene Editing & Gene Therapy Summit in New York City**

- [Matt Kapusta](#), chief executive officer at uniQure, will present a corporate update on Thursday, November 29 at 10:45 a.m. ET. The live webcast can be accessed through the link displayed in the [Investor section of the uniQure website](#). The webcast replay will be available for at least 72 hours following the live event.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases. www.uniQure.com

uniQure Contacts

For Investors:

Maria E. Cantor

Direct: 339-970-7536

Mobile: 617-680-9452

m.cantor@uniQure.com

Eva M. Mulder

Direct: +31 20 240 6103

Mobile: +31 6 52 33 15 79

e.mulder@uniQure.com

For Media:

Tom Malone

Direct: 339-970-7558

Mobile: 339-223-8541

t.malone@uniQure.com